The short version of REV-ERB fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-25 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Fossil dinosaur eggshells, like modern bird and reptile eggshells, are made up of calcium carbonate crystal units. The basic arrangement and structure of these eggshell units (called the ultrastructure) is used to divide fossil eggs into several basic types, including the spherulitic, prismatic, and ornithoid basic types, which contain dinosaurs. Dinosaur eggs further classified by the microstructural aspects of the crystalline structure of the eggshell units and by the type of their pores and their shell ornamentation.
Tizanidine, sold under the brand names Zanaflex and Sirdalud among others, is an α2-adrenergic receptor agonist and muscle relaxant which is used to treat muscle spasticity due to spinal cord injury, multiple sclerosis, and spastic cerebral palsy. Its effectiveness appears to be similar to that of other muscle relaxants like baclofen or diazepam. The drug is taken orally. Common side effects of tizanidine include sleepiness, dry mouth, asthenia, dizziness, low blood pressure, and low heart rate. Serious side effects may include dangerously low blood pressure, liver problems, and psychosis. It is unclear if use in pregnancy and breastfeeding is safe. The drug is an α2-adrenergic receptor agonist, but how it works is not entirely clear. Tizanidine was approved for medical use in the United States in 1996. It is available as a generic medication. In 2023, it was the 81st most commonly prescribed medication in the United States, with more than 8 million prescriptions.
==== Distribution ==== Enobosarm is a small-molecule and highly lipophilic compound. Compounds of this type are typically able to diffuse freely through biological membranes such as cell membranes and barriers like the blood–brain barrier. This is in fact essential for the action of nuclear receptor ligands like enobosarm since their biological targets (the androgen receptor in this case) are located intracellularly. One in silico study predicted that, on the basis of its overall physicochemical properties (but not considering active transport), enobosarm would be unlikely to cross the blood–brain barrier and hence would be a peripherally selective drug with reduced or no central nervous system effects. However, in a rat tissue distribution study, enobosarm was found to be concentrated in brain tissues to a similar extent as other target tissues like skeletal muscle, bone, prostate, and seminal vesicles. This is consistent with enobosarm producing centrally mediated effects in humans like suppression of LH and FSH secretion. Enobosarm does not bind to sex hormone-binding globulin.
With the exception of dual flow (see below) CCC, most countercurrent chromatography modes of operation have a stationary phase and a mobile phase. Even in this situation, countercurrent flows occur within the instrument column. Several researchers have proposed renaming both CCC & CPC to liquid-liquid chromatography, but others feel the term "countercurrent" itself is a misnomer. Unlike column chromatography and HPLC, countercurrent chromatography operators can inject large volumes relative to column volume. Typically 5 to 10% of coil volume can be injected. In some cases this can be increased to as high as 15 to 20% of the coil volume. Typically, most modern commercial CCC and CPC can inject 5 to 40 g/L capacity. The range is so large, even for a specific instrument, let alone all instrument options, as the type of target, matrix and available biphasic solvent vary so much. Approximately 10 g/L would be a more typical value, that the majority of applications could use as a base value. The countercurrent separation starts with choosing an appropriate biphasic solvent system for the desired separation. A wide array of biphasic solvent mixtures are available to the CCC practitioner including the combination n-hexane (or heptane), ethyl acetate, methanol and water in different proportions. This basic solvent system is sometimes referred to as the HEMWat solvent system. The choice of solvent system may be guided by perusal of the CCC literature. The familiar technique of thin layer chromatography may also be employed to determine an optimal solvent system.
Sources: en.wikipedia.org
Ion exchange chromatography can be used to separate proteins because they contain charged functional groups. The ions of interest (in this case charged proteins) are exchanged for another ions (usually H+) on a charged solid support. The solutes are most commonly in a liquid phase, which tends to be water. Take for example proteins in water, which would be a liquid phase that is passed through a column. The column is commonly known as the solid phase since it is filled with porous synthetic particles that are of a particular charge. These porous particles are also referred to as beads, may be aminated (containing amino groups) or have metal ions in order to have a charge. The column can be prepared using porous polymers, for macromolecules of a mass of over 100 000 Da, the optimum size of the porous particle is about 1 μm2. This is because slow diffusion of the solutes within the pores does not restrict the separation quality. The beads containing positively charged groups, which attract the negatively charged proteins, are commonly referred to as anion exchange resins. The amino acids that have negatively charged side chains at pH 7 (pH of water) are glutamate and aspartate. The beads that are negatively charged are called cation exchange resins, as positively charged proteins will be attracted. The amino acids that have positively charged side chains at pH 7 are lysine, histidine and arginine. The isoelectric point is the pH at which a compound—in this case a protein—has no net charge.
=== Recent studies === A 2019 study looked at freeze-dried extracts of the Rotheca myricoides and found that they possess significant anti-hyperglycemic and antidyslipidemic effects on a type 2 diabetes rat model. The antidyslipidemic effects included decreased total plasma cholesterol, LDL-cholesterol, serum triglyceride and increased HDL-cholesterol. The freeze-dried extracts also lowered the serum uric levels and hepatic triglycerides and hepatic weight. This study confirms the effectiveness of the traditional medicine to manage diabetes in Kenya. The mechanism for the antidiabetic effects is due to the modulation of PPAR-γ. A 2008 study found that Rotheca myricoides had antimutagenic properties. The leaf extract of the species and DCM and MeOH extracts shows clear anti-mutagenicity. The antimutagenic properties were seen even at low doses of 0.05 mg/L. Rotheca myricoides is one ingredient (along with four African medicinal plants: Clerodendrum glabrum E. Mey., Lamiaceae, Gladiolus dalenii van Geel, and Senna occidentalis (L.) Link) in a new COVID-19 therapeutic candidate called PHELA. In vitro testing found that PHELA inhibited >90% of SARS-CoV-2 and SARS-CoV infection at concentration levels of 0.005 mg/mL to 0.03 mg/mL. They also found that PHELA had very strong binding energy interactions with SARS-CoV-2 proteins.
In 2025, Newsom signed a budget that restricted new enrollment of undocumented immigrants in Medi-Cal. Newsom signed the California Senate Bill 41 (2025) but vetoed other measures to regulate pharmacy benefit managers.
== Proteolysis and diseases == Abnormal proteolytic activity is associated with many diseases. In pancreatitis, leakage of proteases and their premature activation in the pancreas results in the self-digestion of the pancreas. People with diabetes mellitus may have increased lysosomal activity and the degradation of some proteins can increase significantly. Chronic inflammatory diseases such as rheumatoid arthritis may involve the release of lysosomal enzymes into extracellular space that break down surrounding tissues. Abnormal proteolysis may result in age-related neurological diseases such as Alzheimer's disease due to the generation and ineffective removal of peptides that aggregate in cells. Proteases may be regulated by antiproteases or protease inhibitors, and imbalance between proteases and antiproteases can result in diseases, for example, in the destruction of lung tissues in emphysema brought on by smoking tobacco. Smoking is thought to increase the neutrophils and macrophages in the lung which release excessive amount of proteolytic enzymes such as elastase, such that they can no longer be inhibited by serpins such as α1-antitrypsin, thereby resulting in the breaking down of connective tissues in the lung. Other proteases and their inhibitors may also be involved in this disease, for example matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). Other diseases linked to aberrant proteolysis include muscular dystrophy, degenerative skin disorders, respiratory and gastrointestinal diseases, and malignancy.
The band had another stylistic change with the recording of Signals in 1982. While Lee's synthesizers had been featured instruments since the late 1970s, keyboards were shifted from the background to the melodic front-lines in songs like "Countdown" and the opening track, "Subdivisions". Both feature prominent lead synthesizer lines with minimalistic guitar chords and solos. Other previously unused instrument additions were seen in the song "Losing It", featuring collaborator Ben Mink on electric violin.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.